NZ718190A - Substituted quinazolines for inhibiting kinase activity - Google Patents

Substituted quinazolines for inhibiting kinase activity

Info

Publication number
NZ718190A
NZ718190A NZ718190A NZ71819014A NZ718190A NZ 718190 A NZ718190 A NZ 718190A NZ 718190 A NZ718190 A NZ 718190A NZ 71819014 A NZ71819014 A NZ 71819014A NZ 718190 A NZ718190 A NZ 718190A
Authority
NZ
New Zealand
Prior art keywords
kinase activity
inhibiting kinase
substituted quinazolines
kinase inhibitors
quinazolines
Prior art date
Application number
NZ718190A
Other languages
English (en)
Inventor
Xiangping Qian
Yong-Liang Zhu
Original Assignee
Neupharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neupharma Inc filed Critical Neupharma Inc
Publication of NZ718190A publication Critical patent/NZ718190A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5758—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ718190A 2013-08-23 2014-08-22 Substituted quinazolines for inhibiting kinase activity NZ718190A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361869596P 2013-08-23 2013-08-23
US201361900283P 2013-11-05 2013-11-05
US201462000946P 2014-05-20 2014-05-20
PCT/US2014/052409 WO2015027222A2 (en) 2013-08-23 2014-08-22 Certain chemical entities, compositions, and methods

Publications (1)

Publication Number Publication Date
NZ718190A true NZ718190A (en) 2017-10-27

Family

ID=52484273

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ718190A NZ718190A (en) 2013-08-23 2014-08-22 Substituted quinazolines for inhibiting kinase activity

Country Status (20)

Country Link
US (8) US9550770B2 (enExample)
EP (1) EP3035936B1 (enExample)
JP (1) JP6559132B2 (enExample)
KR (1) KR102339228B1 (enExample)
CN (3) CN105682661B (enExample)
AU (3) AU2014308616B2 (enExample)
BR (1) BR112016005199B1 (enExample)
CA (1) CA2921410C (enExample)
DK (1) DK3035936T3 (enExample)
ES (1) ES2729381T3 (enExample)
HU (1) HUE043465T2 (enExample)
IL (2) IL244189B (enExample)
MX (1) MX369863B (enExample)
NZ (1) NZ718190A (enExample)
PH (2) PH12019500143B1 (enExample)
PL (1) PL3035936T3 (enExample)
PT (1) PT3035936T (enExample)
RU (1) RU2718876C2 (enExample)
SG (2) SG10201908045VA (enExample)
WO (1) WO2015027222A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
PL3035936T3 (pl) 2013-08-23 2019-08-30 Neupharma, Inc. Pewne jednostki chemiczne, kompozycje i sposoby
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN107613769A (zh) 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
SG11201706869XA (en) 2015-03-24 2017-09-28 Shanghai Yingli Pharm Co Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
EP3287463A4 (en) * 2015-04-24 2018-07-11 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
CN113999180B (zh) * 2015-07-03 2024-03-26 上海医药集团股份有限公司 喹唑啉类化合物、其中间体、制备方法、药物组合物和应用
AU2016295594B2 (en) * 2015-07-21 2020-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
PT3889145T (pt) 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
CN106243044A (zh) * 2016-06-30 2016-12-21 浙江大学 含卤代丙烯酰胺侧链的嘧啶类衍生物及制备和应用
CN106279027A (zh) * 2016-07-26 2017-01-04 沈阳药科大学 (1‑芳基‑1h‑吡唑‑4‑基)(3,4,5‑三甲氧基苯基)甲酮、甲酮肟类化合物及其用途
CN106187923A (zh) * 2016-08-01 2016-12-07 沈阳药科大学 2‑芳基‑4‑芳酰基‑三氮唑类化合物及其用途
CN109563075B (zh) 2016-08-08 2022-09-30 默克专利股份公司 Tlr7/8拮抗剂及其用途
JP7101165B2 (ja) * 2016-08-15 2022-07-14 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
MY199852A (en) * 2016-11-28 2023-11-25 Teijin Pharma Ltd Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof
PT3546458T (pt) * 2016-11-28 2021-02-25 Teijin Pharma Ltd Derivados de ((piridin-2-il)-amino)pirido[3,4-d]pirimidina e ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina como inibidores de cdk4/6 para tratamento p.e. da artrite reumatoide, arteriosclerose, fibrose pulmonar, enfarte cerebral ou cancro
WO2018140598A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Fused n-heterocyclic compounds and methods of use thereof
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
FR3066761B1 (fr) 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
AU2018325442B2 (en) * 2017-08-31 2023-04-13 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and/or HER2 and methods of use
KR102613433B1 (ko) * 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
JP7550646B2 (ja) * 2018-02-08 2024-09-13 ニューファーマ，インク． 特定の化学物質、組成物、および方法
CN108690389A (zh) * 2018-04-23 2018-10-23 河北晨阳工贸集团有限公司 一种led光固化水性木器漆及其制备方法
CN112584833A (zh) 2018-08-01 2021-03-30 亚瑞克西斯制药公司 杂环螺化合物及其用于治疗癌症的使用方法
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
JP2022515198A (ja) * 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
EP4116305A4 (en) * 2020-03-06 2024-07-17 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. THIENOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREFOR
WO2021180032A1 (en) * 2020-03-13 2021-09-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Novel Therapeutic Methods
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN115942937B (zh) * 2020-08-17 2025-07-25 浙江扬厉医药技术有限公司 嘧啶并环类化合物
US11548885B2 (en) 2020-09-21 2023-01-10 Landos Biopharma, Inc. NLRX1 ligands
CN117836286A (zh) * 2021-06-22 2024-04-05 缆图药品公司 用于治疗癌症的杂环egfr抑制剂
WO2022271749A1 (en) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
CN117940424A (zh) * 2021-06-22 2024-04-26 缆图药品公司 Egfr抑制剂
CN117858872A (zh) * 2021-06-22 2024-04-09 缆图药品公司 用于治疗癌症的杂环egfr抑制剂
CN115583946B (zh) * 2021-07-06 2026-01-16 赛诺哈勃药业（成都）有限公司 杂环化合物及其作为cdk抑制剂的用途
WO2023010354A1 (zh) * 2021-08-04 2023-02-09 四川大学华西医院 一种具有egfr抑制活性的小分子化合物及其制备方法与应用
WO2023071998A1 (zh) * 2021-10-26 2023-05-04 杭州德睿智药科技有限公司 新型嘧啶或三嗪取代吡啶并杂环化合物
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
PE20250268A1 (es) 2022-04-28 2025-01-29 Astrazeneca Ab Compuestos heteroaromaticos biciclicos condensados y uso en el tratamiento del cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
KR20250029133A (ko) 2022-06-27 2025-03-04 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2025010279A2 (en) * 2023-07-03 2025-01-09 Resero Therapeutics, Llc. Polo-like kinase 1 inhibitors
WO2025235874A1 (en) * 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587936A (en) 1944-09-05 1947-05-09 Francis Henry Swinden Curd New quinazoline derivatives
GB8515934D0 (en) 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997029106A1 (en) 1996-02-12 1997-08-14 Rutgers, The State University Of New Jersey Coralyne analogs as topoisomerase inhibitors
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JP3990061B2 (ja) 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
CA2315736A1 (en) 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05708B1 (et) 1999-02-10 2014-04-15 Astrazeneca Ab Kinasoliini derivaat angiogeneesi inhibiitorina ja selle kasutamine
CA2376835C (en) 1999-07-02 2009-09-15 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
DE60030741T2 (de) * 1999-09-23 2007-09-06 Astrazeneca Ab Chinazoline verbindungen als heilmittel
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
CA2517034A1 (en) 2003-03-13 2004-09-30 Synta Pharmaceuticals Corp. Fused pyrrole compounds
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
PL2215094T3 (pl) 2007-11-15 2016-09-30 Związki heterocykliczne zawierające n
US20110039845A1 (en) * 2008-04-23 2011-02-17 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
US8252791B2 (en) 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
WO2010056758A1 (en) 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
CA2776308C (en) 2009-10-07 2020-01-28 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US20110207736A1 (en) * 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
FR2959510B1 (fr) * 2010-04-28 2013-04-26 Centre Nat Rech Scient Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
CN102260263A (zh) 2010-05-26 2011-11-30 四川大学 一类二苯胺基嘌呤衍生物及制备方法和医药用途
US8703767B2 (en) 2011-04-01 2014-04-22 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
WO2013005157A1 (en) 2011-07-05 2013-01-10 Lupin Limited Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
KR101410902B1 (ko) 2011-07-27 2014-06-20 아스트라제네카 아베 암 치료에 유용한 egfr 조절물질로서 2-(2,4,5-치환된-아닐리노)피리미딘 유도체
AU2012300317B2 (en) 2011-08-26 2016-12-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9518029B2 (en) 2011-09-14 2016-12-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN107898790B (zh) 2011-11-30 2024-06-21 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
HK1203927A1 (en) 2012-01-13 2015-11-06 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents
TW201336847A (zh) 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
US9394297B2 (en) * 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
PL2872491T3 (pl) 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitory receptora czynnika wzrostu fibroblastów
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
TW201427958A (zh) 2012-09-14 2014-07-16 Univ Nat Yang Ming 芳基胺取代之嘧啶及喹唑啉及其作為抗癌藥物之用途
AU2013323360B2 (en) 2012-09-28 2017-09-07 Cancer Research Technology Limited Azaquinazoline inhibitors of atypical protein kinase C
CN103864792B (zh) 2012-12-12 2017-01-18 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮并环类化合物
CN103936742B (zh) 2013-01-17 2017-05-03 程鹏 含嘌呤基的新型pi3k抑制剂及其制备方法和应用
WO2014130693A1 (en) 2013-02-25 2014-08-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9617266B2 (en) 2013-03-05 2017-04-11 Merck Patent Gmbh Imidazopyrimidine derivatives
ES2642201T3 (es) 2013-03-06 2017-11-15 Astrazeneca Ab Inhibidores de quinazolina de formas mutantes de activación del receptor del factor de crecimiento epidérmico
JP6401247B2 (ja) 2013-05-06 2018-10-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ阻害剤としての大員環化合物
CN103554038B (zh) 2013-06-19 2015-10-14 云南大学 多卤代苯腈喹唑啉酮化合物及其制备方法和用途
CN112592334B (zh) 2013-07-11 2023-10-27 艾森医药公司 嘧啶衍生物作为激酶抑制剂
PL2947086T3 (pl) 2013-08-12 2018-06-29 Taiho Pharmaceutical Co., Ltd. Nowy skondensowany związek pirymidynowy lub jego sól
PL3035936T3 (pl) 2013-08-23 2019-08-30 Neupharma, Inc. Pewne jednostki chemiczne, kompozycje i sposoby
US20160272645A1 (en) 2013-10-18 2016-09-22 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
GB201404987D0 (en) 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015175813A1 (en) 2014-05-14 2015-11-19 The Regents Of The University Of Colorado, A Body Corporate Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
CN104086551B (zh) 2014-06-06 2016-09-21 人福医药集团股份公司 化合物及其制备方法和用途
TW201613644A (en) 2014-06-17 2016-04-16 Acerta Pharma Bv Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
CN105315283A (zh) 2014-07-22 2016-02-10 成都贝斯凯瑞生物科技有限公司 一种Bruton酪氨酸激酶抑制剂
EP3174539A4 (en) 2014-08-01 2017-12-13 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase
US10435402B2 (en) 2015-01-08 2019-10-08 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
CN105837576B (zh) 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
CN107613769A (zh) 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
CN105777759B (zh) 2016-04-29 2018-01-26 杭州和正医药有限公司 一种布鲁顿酪氨酸激酶抑制剂
JP7101165B2 (ja) 2016-08-15 2022-07-14 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法

Also Published As

Publication number Publication date
US9550770B2 (en) 2017-01-24
MX369863B (es) 2019-11-25
JP2016530274A (ja) 2016-09-29
US10172868B2 (en) 2019-01-08
WO2015027222A3 (en) 2015-04-16
IL244189A0 (en) 2016-04-21
US20190307767A1 (en) 2019-10-10
EP3035936A4 (en) 2017-03-08
AU2014308616A1 (en) 2016-03-10
CN109851617B (zh) 2022-08-16
BR112016005199B1 (pt) 2022-02-22
US20220354864A1 (en) 2022-11-10
US12403145B2 (en) 2025-09-02
US9849139B2 (en) 2017-12-26
RU2016110412A3 (enExample) 2018-06-22
SG10201908045VA (en) 2019-10-30
CN111285813A (zh) 2020-06-16
US20150175601A1 (en) 2015-06-25
IL268094B (en) 2020-07-30
HUE043465T2 (hu) 2019-08-28
CN105682661B (zh) 2020-03-27
AU2019201461A1 (en) 2019-03-28
EP3035936B1 (en) 2019-03-13
SG11201601138PA (en) 2016-03-30
BR112016005199A2 (enExample) 2017-08-01
KR102339228B1 (ko) 2021-12-13
AU2021200372A1 (en) 2021-03-18
US20170196881A1 (en) 2017-07-13
US20200306259A1 (en) 2020-10-01
JP6559132B2 (ja) 2019-08-14
CA2921410A1 (en) 2015-02-26
PH12016500330B1 (en) 2016-05-02
RU2718876C2 (ru) 2020-04-15
CN109851617A (zh) 2019-06-07
IL244189B (en) 2019-08-29
PH12019500143A1 (en) 2020-03-02
KR20160090786A (ko) 2016-08-01
EP3508204A1 (en) 2019-07-10
US11304957B2 (en) 2022-04-19
HK1226939A1 (en) 2017-10-13
PL3035936T3 (pl) 2019-08-30
MX2016002137A (es) 2017-02-15
RU2016110412A (ru) 2017-09-26
PH12019500143B1 (en) 2023-03-24
DK3035936T3 (da) 2019-06-11
AU2014308616B2 (en) 2018-12-06
US11865120B2 (en) 2024-01-09
AU2021200372B2 (en) 2023-09-21
AU2019201461B2 (en) 2020-11-12
IL268094A (en) 2019-09-26
US10653701B2 (en) 2020-05-19
CA2921410C (en) 2023-03-28
WO2015027222A2 (en) 2015-02-26
US20240197752A1 (en) 2024-06-20
EP3035936A2 (en) 2016-06-29
CN105682661A (zh) 2016-06-15
PH12016500330A1 (en) 2016-05-02
US20170050936A1 (en) 2017-02-23
ES2729381T3 (es) 2019-11-04
US20180125855A1 (en) 2018-05-10
PT3035936T (pt) 2019-06-18

Similar Documents

Publication Publication Date Title
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
IL291000A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for cancer therapy
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
NZ724691A (en) Quinoline derivatives as smo inhibitors
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
PH12016502453B1 (en) Heteroaryl compounds for kinase inhibition
MX2015000129A (es) Derivados de pirimidin pirazolilo.
MX2016007885A (es) Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
MX2019003942A (es) Anticuerpos anti-pd-l1 y antagonistas de vegf y su uso en el tratamiento del cancer.
MX2016005297A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2015011428A (es) Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX2018003563A (es) Nuevos compuestos.
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2015013021A (es) 5-bromo-indirrubinas.
IN2014MU00495A (enExample)
MY182434A (en) Certain chemical entities, compositions, and methods
NZ763986A (en) Heteroaryl compounds for kinase inhibition

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2019 BY COMPUTER PACKAGES INC

Effective date: 20180731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2020 BY COMPUTER PACKAGES INC

Effective date: 20190731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2021 BY COMPUTER PACKAGES INC

Effective date: 20200731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2022 BY COMPUTER PACKAGES INC

Effective date: 20210730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2023 BY COMPUTER PACKAGES INC

Effective date: 20220730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2024 BY COMPUTER PACKAGES INC

Effective date: 20230730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2025 BY COMPUTER PACKAGES INC

Effective date: 20240730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2026 BY COMPUTER PACKAGES INC

Effective date: 20250830